Health~Holland International’s Post

Healthcare is entering a defining moment, with an opportunity to embrace a new wave of innovation. Yet if Europe is to realise the full potential of these breakthroughs, it is vital that people across the region have more timely and equitable access to these treatments.   It is with this potential in mind that I take up a new position on the Board of the European Federation of Pharmaceutical Industries and Associations (EFPIA) – the main body representing the research-based biopharmaceutical industry in Europe.   Alongside my peers from world-leading pharmaceutical companies, I will be working to help deliver on EFPIA’s mission to create an environment that enables our industry to innovate, thrive and deliver new therapies across Europe. At Pfizer, our goal is to change the lives of one billion patients a year by 2027 – but as EFPIA’s mission alludes, this is only possible with the right policy and legislative environment in place.   Europe is often seen as a pharmaceutical powerhouse, with the skilled workforce, academic infrastructure, multi-national institutions, and manufacturing capability making it a location of choice for life science investment. Yet in spite of all this expertise and promise there is still significant inequity in access to new medicines. Patients in Europe are having to wait 517 days for access to innovative treatments on average, ranging from 128 days up to a staggering 1,351 days.* This is an unacceptable situation, and I believe our industry is and should remain an important voice in profiling and remedying this issue. Timely and equitable access is a cause I am deeply passionate about. Through my new role on the EFPIA Board, I am committed to finding and fighting for solutions in partnership with policymakers and stakeholders across Europe, based on a shared understanding of the root causes of unavailability and access delays. This is a real opportunity to create a modernised system that can embrace the next generation of medicines and vaccines. Together, I hope we can achieve a healthier and stronger Europe. * https://lnkd.in/egnbJgvd   #EFPIA #HealthPolicy #LifeSciences #HealthofEurope #MedicineAccess  

Congratulations Michael Boyd! You'll be great in this, and I couldn't agree with you more. On that note, here's the link to a nice ebook (just published by the incredible Jill Donahue, Fueling the power of purpose in pharma teams), which tells the stories of 100 pharma leaders, a tool perhaps to leverage in telling a piece of our story: A Dose of Inspiration: 100 Purpose Stories from Pharma Leaders (https://lnkd.in/efCEvCX8)

🔬 Catalonia has become a top destination worldwide and in Europe for the development of clinical trials. 🧪 5,308 clinical trials currently underway. 🌍 No. 8⃣ in the world & No. 5⃣ in Europe. 📍 88.5% of Spain's clinical trials are conducted in the #BioRegionCatalonia. Catalonia particularly excels in #oncology trials, which represent 34% of the total, followed by other therapeutic areas such as the immune system and the respiratory system. The quality of the #health system has attracted top #pharma multinationals such as Novartis, Roche, Bristol Myers Squibb, AstraZeneca, Pfizer, GSK, Sanofi, Eli Lilly and Company, The Janssen Pharmaceutical Companies of Johnson & Johnson, MSD, or AbbVie to Catalonia to develop their trials. 📋 Check the data in the #BioRegionReport 2023: https://report.biocat.cat/ Promoted by: Biocat, BioRegion of Catalonia With the support of: Amgen, Almirall, AstraZeneca, Cuatrecasas, ESTEVE, and Sanofi. In collaboration with: CataloniaBio & HealthTech, ACCIÓ, Farmaindustria, and Fenin, Federación Española de Empresas de Tecnología Sanitaria.

Pharmacovigilance Market Size, Share & Trends Analysis Report By Clinical Trial Phase, By Service Provider, By Type, By End Use, Russia-Ukraine War and COVID-19 Impact Analysis, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast, 2022 - 2028 IMIR Market Research Pvt. Ltd. 📚 Request Sample Report 👉https://lnkd.in/dPFd6dtE 📚Top More Key players Are:👇 AbbVie Amgen Astellas Pharma AstraZeneca Bayer Bioclinica Biogen Boehringer Ingelheim Bristol Myers Squibb Celgene Clinquest, Inc. COVANCE LABORATORIES LIMITED Daiichi Sankyo US. Eli Lilly and Company Foresight Group International AG Gilead Sciences GSK ICON plc iMEDGlobal Corporation IQVIA Johnson & Johnson Merck Group Novartis Parexel Pfizer Roche Sanofi Sciformix TAKE Solutions #pharmacovigilance #intellectualmarketinsights #growth #share #covid19impact #russiaukrainewar #marketresearch #marketresearchreports #northamerica #europe #asiapacific #latinamerica #africa 

A recent report by IQVIA highlights the importance of patient groups in fuelling pharmaceutical development. Here are 5 key findings from the report -   1. Partnerships with pharma companies - Patient groups raise funds from patrons and supporters, which are then utilized to forge partnerships with pharma companies to conduct cutting-edge research. This pathway allows crucial research to identify disease biomarkers and expedite drug development. According to the report, over the past 15 years, patient groups have struck almost 700 deals with drugmakers, totaling $2.4 billion, to address the most glaring needs of patients suffering from various diseases.   2. Supporting clinical trials - Not only do patient groups sponsor clinical trials, but they also encourage and enable eligible patients to enroll in the same, supporting improved patient outcomes and expedited pharmaceutical development.   3. Bringing in the patient perspective - The patient perspective is often lacking from pharmaceutical R&D. Patient groups fill this gap by providing useful patient-valued endpoints to align R&D efforts with the needs of the patient community.   4. Developing patient registries - Patient registries play a crucial role in pharmaceutical R&D and clinical trials, particularly for rare diseases, where the patient population is small and scattered across the globe. A growing number of patient groups have created patient registries that serve as a valuable resource for pharmaceutical development.   5. Advocating access to medicines for all - Patient groups are well-connected global communities that support patients in accessing promising treatments for their conditions. They are often led by patient advocates who run initiatives to bring down the cost of expensive medicines, support local production of patented drugs, and promote recourses such as named patient imports of unlicensed medicines from another country where they have been approved.   Through these meaningful pathways and initiatives, patient groups have become an indispensable part of pharmaceutical development and distribution. By meaningful partnerships between patient groups, pharma companies, and healthcare entities, the goal of "Right To Health For All" seems closer in sight.   Reference - https://lnkd.in/dVTzrvsQ - pharmavoice   #healthforall #righttohealth #patientsfirst #patientadvocacy #patientadvocates #advocacy #healthsystems #pharmaceuticals #medicalaffairs

🔍 What’s stopping pharma companies from running commercial trials in Africa? We agree it's the right and ethical thing to do, yet it isn't happening... No one wants to be the first. eMQT proposes a change! 🌍 Calling all pharma companies committed to diversity in clinical trials. Join us in building Centres of Excellence together! 🌟 Here’s our simple 3-step proposal: 1️⃣ Meet with eMQT to discuss your therapeutic area and patient population focus. 2️⃣ We identify suitable sites and countries in Africa to match your needs. 3️⃣ Collaborate with us to build Centres of Excellence! Let’s lead the way in transforming clinical research.💡🤝 #DiversityInTrials #ClinicalResearch #PharmaInnovation Contact us today to start the journey! 🌟 https://buff.ly/40eOKUb Pfizer Roche AstraZeneca Gilead Sciences Vertex Pharmaceuticals Veramed Takeda GSK Genentech Novartis Moderna Shalom Ijeoma Lloyd MBE Tina Barton Emily Moore Hannah White Nancy Meyerson-Hess

Pharmacovigilance Market Size, Share & Trends Analysis Report By Clinical Trial Phase, By Service Provider, By Type, By End Use, Russia-Ukraine War and COVID-19 Impact Analysis, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast, 2022 - 2028 IMIR Market Research Pvt. Ltd. 📚 Request Sample Report 👉https://lnkd.in/dPFd6dtE 📚Top More Key players Are:👇 AbbVie Amgen Astellas Pharma US AstraZeneca Bayer Bioclinica Biogen Boehringer Ingelheim Bristol Myers Squibb Celgene Clinquest, Inc. COVANCE LABORATORIES LIMITED Daiichi Sankyo US. Eli Lilly and Company Foresight Group International AG Gilead Sciences GSK ICON plc iMEDGlobal Corporation IQVIA Johnson & Johnson Merck Group Novartis Parexel Pfizer Roche Sanofi Sciformix TAKE Solutions #pharmacovigilance #intellectualmarketinsights #growth #share #covid19impact #russiaukrainewar #marketresearch #marketresearchreports #northamerica #europe #asiapacific #latinamerica #africa 

GSK to infuse £200M into UK manufacturing, pharma API In a strategic move to fortify its manufacturing capabilities, GlaxoSmithKline (GSK) is demonstrating a steadfast commitment to the United Kingdom, announcing an investment exceeding £200 million ($253 million) by 2025. The pharmaceutical giant is channeling substantial resources into enhancing its U.K. supply network, encompassing the construction of new facilities and the development of innovative assembly lines. A pivotal aspect of this initiative is the ongoing £67 million ($85 million) upgrade to GSK's manufacturing site in Montrose, Scotland. Scheduled for completion this year, the upgraded facility will play a crucial role in producing active pharmaceutical ingredients (API) to support the future supply of medicines. Furthermore, GSK is set to commence operations at its £65 million ($82 million) site in Ware, England, which commenced operations in September. This global manufacturing hub for GSK will be pivotal in manufacturing some of the company's most "commercially important" medicines, including those addressing HIV. GSK's commitment to the U.K. is underscored by its investment in six manufacturing sites across the country. This strategic move stands in contrast to some industry peers, such as AstraZeneca, which opted for international expansion, citing concerns about the U.K.'s tax policies. Notably, GSK is not limiting its investments to the U.K., recently pledging 250 million euros ($273 million) for a state-of-the-art facility at its Wavre campus in Belgium, supporting the company's burgeoning vaccine ambitions, including the launch of its RSV shot, Arexvy. As GSK forges ahead with these strategic investments, it solidifies its position as a key player in the global pharmaceutical landscape. #api #pharmamanufacturing #biotech #bigpharma #sanofi #gsk #pfizer #sunpharma #cipla #lupin #drreddys #pharmamarketing #pharmacompanies

𝐅𝐫𝐢𝐝𝐚𝐲 𝐅𝐥𝐚𝐬𝐡𝐛𝐚𝐜𝐤 OPEX Sanofi Sanofi is a multinational pharmaceutical company headquartered in Paris, France. It is one of the largest pharmaceutical companies globally, with a focus on research, development, manufacturing, and marketing of pharmaceutical products. Sanofi operates in various therapeutic areas, including diabetes, cardiovascular diseases, vaccines, rare diseases, oncology, and consumer healthcare. Sanofi Pasteur, the vaccine division of Sanofi, develops and manufactures vaccines. Because of quality issues, these vaccines were not always available to all. Public health was at risk and the cost to business was high. Successive top-down programs brought little sustainable improvement. The short term strategy was to create an activist, peer-to-peer movement for change and improvement. In the long term, with the credibility granted by its first successes, this movement becomes a new way of working for the whole company. As a result, operational performance has massively improved. In just 1 year, human errors are down by - 18% (down by 91% in some areas!); recurring deviations -25%; right-first-time +20%; corrective action timeliness +45%; vaccine supply has been debottlenecked. Sanofi Pasteur is achieving both outstanding business results and a profound business transformation. 𝐂𝐨𝐧𝐬𝐮𝐥𝐭𝐢𝐧𝐠 | 𝐂𝐨𝐚𝐜𝐡𝐢𝐧𝐠 | 𝐂𝐨𝐧𝐧𝐞𝐜𝐭𝐢𝐧𝐠 www.effortsconsulting.com https://lnkd.in/darPP_zj www.leanext.co.in Dr. Japan Trivedi Dhruvang Dhamecha Milap Shah #leansixsigma #leanmanufacturing #leanseissigma #leanstartups #leanmanagement #leansixsigmablackbelt #leansixsigmagreenbelt #leansixsigmacertification #leanprojects #leanstartups #leantransformation #sixsigmagreenbelt #sixsigmablackbel #sixsigmatrainin #opex #pharmaindustry #opex #leanmanagement #improvement #Leanway